Abstracts tagged "DMARDs and combination therapies"

Abstract Number: 1055 • ACR/ARHP Annual Meeting 2013
Discontinuation Rates In Patients With RA Of Triple Disease Modifying Antirheumatic Therapy
Sofia Pedro¹, Frederick Wolfe¹, Hawre Jalal² and Kaleb Michaud³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Health Polisy and Management, University of Minnesota, Minneapolis, MN, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Drug discontinuation rates are measures of effectiveness and are needed in health economic models. While a recent RCT demonstrated statistical equivalence of efficacy with…
Abstract Number: 1300 • ACR/ARHP Annual Meeting 2012
Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Dimitrios A. Pappas¹, George W. Reed², Katherine C. Saunders³, Ani John⁴, Ashwini Shewede⁴, Jenny Devenport⁵, Jeffrey D. Greenberg⁶ and Joel M. Kremer⁷, ¹Columbia University, New York, NY, ²University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Genentech Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Approximately one-third of RA patients were prescribed biologic (Bio) monotherapy (MT) i.e. without concomitant disease-modifying anti-rheumatic drugs (DMARD) (Yazici et al., 2008). The purpose…